Lapatinib as a small molecule dual tyrosine kinase inhibitor of EGFR and HER-2 has been demonstrated the ability to prevent the rebound of the ERK signaling and sensitize BRAF-mutant thyroid cancer cells to RAF or MEK inhibitors [10]. Here, MAP2K7 is linked to thyroid cancer.